Breaking

Oscar-winning actress Eva Marie Saint dies aged 102 A ‘Godzilla-level’ El Niño is causing extreme weather conditions around the world – put your questions to our environment writers Arteta signs new contract with champions Arsenal Sen. Ruben Gallego rolls out an economic agenda as he weighs a 2028 White House bid They were a historically bad team. Now they’re a threat to make the World Series. Meta’s Oversight Board has a warning for AI companies building their own watchdogs The Spin | Schrödinger’s six, tiny boundaries and the hollow spectacle of ghost-town T10 cricket Freddie Jackson, romantic US singer with 10 R&B chart-toppers, dies aged 70 IMF chief urges governments to tighten belts as global debt levels soar Trump’s LA and San Diego comments ‘dangerous, if not treasonous’, says Newsom – US politics live

NEWSREEL

The day, in 30-second reels.

--:--:--

Science / Reel

Science · Video brief

The mRNA technology behind Moderna’s Covid vaccine reaches the flu

The FDA has approved Moderna's new mRNA flu vaccine, mFlusiva, specifically for adults aged 50 and older. In trials, it demonstrated a 27% reduction in flu cases, offering a promising tool to tackle evolving flu mutations.

The Guardian· Aug 6, 2026 · 3:44 PM · 37 views

Video won't play? Watch on YouTube →

The FDA has approved Moderna's new mRNA flu vaccine, mFlusiva, specifically for adults aged 50 and older. In trials, it demonstrated a 27% reduction in flu cases, offering a promising tool to tackle evolving flu mutations. Full story and more reels: https://newsreel.video #news #breaking #health #vaccine #mRNA #flu #Moderna #FDA

Originally reported by The Guardian. Read the full story →

More in Science

A ‘Godzilla-level’ El Niño is causing extreme weather conditions around the world – put your questions to our environment writers

The Guardian· 1 hour ago

Leicester hooker Theobald-Thomas forced to retire

BBC Sport· 1 hour ago

Nobel prize in physics goes to Francis Halzen for south pole work on neutrinos

The Guardian· 9 hours ago

0 Comments

No comments yet. Be the first.